More on Cancer, A Fib

[Guest guest]

February 16, 2011

Researchers from Jefferson's Kimmel Cancer Center have genetic evidence

suggesting the antioxidant drugs currently used to treat lung disease, malaria

and even the common cold can also help prevent and treat cancers because they

fight against mitochondrial oxidative stress-a culprit in driving tumor growth.

For the first time, the researchers show that loss of the tumor suppressor

protein Caveolin-1 (Cav-1) induces mitochondrial oxidative stress in the stromal

micro-environment, a process that fuels cancer cells in most common types of

breast cancer. More............

http://www.medicalnewstoday.com/articles/216559.php

*************************

The ASCO Cancer Foundation Relaunches As Conquer Cancer FoundationArticle Date:

15 Feb 2011

Today marks the official launch of the Conquer Cancer Foundation of the American

Society of Clinical Oncology (ASCO), the premier philanthropic organization

working to ensure all people have access to high-quality cancer care. Formerly

known as The ASCO Cancer Foundation, the Conquer Cancer Foundation is dedicated

to creating a world free from the fear of cancer. Working in close collaboration

with a global network of top scientists and clinical researchers, as well as

leading advocacy and research organizations, the Foundation draws on the passion

and expertise of the nearly 30,000 oncology professionals who are members of

ASCO, the Foundation's affiliate organization.

" Now we have genetic proof that mitochondrial oxidative stress is important for

driving tumor growth, " said lead researcher P. nti, M.D., Ph.D.,

professor of cancer biology at Jefferson Medical College of Jefferson

University and member of the Kimmel Cancer Center at Jefferson. " This means we

need to make anti-cancer drugs that specially target this type of oxidative

stress. And there are already antioxidant drugs out there on the market as

dietary supplements, like N-acetyl cysteine. " More..........

http://www.medicalnewstoday.com/articles/216483.php

*******************************

Potential Cancer Therapy Target

Article Date: 15 Feb 2011

One of the most important genes in the human genome is called p53 and its

function is to suppress tumours, according to Leng, a researcher in the

Faculty of Medicine & Dentistry. Leng has discovered the mechanism by which p53

is inactivated in cancerous cells, allowing tumours to grow.

" Successful completion of the proposed experiments could lead to novel

anti-cancer therapies that could potentially improve the prognosis for cancer

patients and reduce the public health burden from cancer, " said Leng.

http://www.medicalnewstoday.com/articles/216481.php

**************************************

Collaboration On Worldwide AF Awareness Campaign

Article Date: 16 Feb 2011

The World Heart Federation, sanofi-aventis and Boehringer Ingelheim have

announced their collaboration on the AF AWARE (Atrial Fibrillation AWareness And

Risk Education) campaign today, to raise awareness of atrial fibrillation (AF)

and its links to severe consequences including cardiovascular (CV) mortality,

stroke and CV hospitalizations. The campaign aims to promote education around

the risks associated with AF as well as highlight the importance of early

diagnosis and comprehensive management to maximize patient outcomes.

" AF is a growing public health issue, affecting not only the patients who live

with the condition, but also their families and the healthcare systems in the

countries where they live. Yet research shows there is a perceived lack of

awareness and understanding of this condition, " said Johanna Ralston, Chief

Executive Officer, World Heart Federation. " The AF AWARE campaign was

established to specifically address the lack of awareness and endeavours to draw

attention to this serious, chronic, disease, the consequences of which can have

devastating effects on patients and healthcare systems. " Read

more................

http://www.medicalnewstoday.com/articles/216564.php

*****************************

FYI,

Lottie Duthu